Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Uncover prior art in abandoned patent applications and expired patents
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 5,252,341

« Back to Dashboard

Summary for Patent: 5,252,341

Title: Tablets and granulates containing mesna as active substance
Abstract:A granulate containing mesna is made by granulating mesna in the presence of an alcohol, acetone or a mixture of one of these with water. The granulate may be converted to tablets, along with other agents. The tablets contain 0.01-1 parts by weight of a binding agent 0.03-0.4 parts by weight of a disintegrant 0.01-0.2 parts by weight of a lubricant and 0.1-1 parts by weight of a filling agent as well as, in the case of an effervescent tablet, an additional 0.05-30 parts by weight of a conventional physiologically acceptable effervescent mixture.
Inventor(s): Sauerbier; Dieter (Werter, DE), Engel; Jurgen (Alzenau, DE), Milsmann; Eckhard (Bielefeld, DE)
Assignee: Degussa Aktiengesellschaft (DE)
Application Number:07/930,783
Patent Claim Types:
see list of patent claims
Composition; Process; Formulation;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,252,341

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany4022525Jul 16, 1990

International Patent Family for Patent: 5,252,341

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria104548► Subscribe
Australia638586► Subscribe
Australia8044591► Subscribe
Bulgaria60851► Subscribe
Bulgaria60901► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.